Last reviewed · How we verify
FP 0.05%
At a glance
| Generic name | FP 0.05% |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Analgosedation for Elective Colonoscopy (PHASE1)
- Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl (PHASE4)
- A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis (PHASE4)
- Fluticasone Nasal Spray Patient Preference Study (PHASE3)
- A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo (PHASE2)
- Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children (PHASE3)
- Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FP 0.05% CI brief — competitive landscape report
- FP 0.05% updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI